Mariela Ibarra Salce

Dr. Mariela Ibarra Salce

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
Jose Luis Eduardo Doval CaballeroJose Luis Eduardo Doval Caballero
Jose Luis Eduardo Doval Caballero
DUDaniel Uribe-Cortés
Daniel Uribe-Cortés
GEGenesis Dinora Eugenio-Ponce
Genesis Dinora Eugenio-Ponce
MSMariela Ibarra Salce
Mariela Ibarra Salce
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
Background/Objectives: Type 2 diabetes is increasingly recognized as a systemic disorder driven not only by chronic hyperglycemia and insulin resistance, but also by dysregulated interorgan communication. Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as biologically active carriers of proteins, lipids, and microRNAs capable of modulating gene expression in recipient cells. This narrative review integrates clinical, experimental, and translational evidence on EV-associated microRNAs as candidate biomarkers and potential mediators of diabetic complications, with emphasis on diabetic neuropathy, diabetic kidney disease, diabetic retinopathy, and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This review was aligned with the SANRA framework and focused on biological plausibility, evidence from tissue and biofluids, biomarker potential, therapeutic implications, and barriers to clinical translation. Studies were additionally interpreted according to biological matrix, EV-carrier specificity, analytical platform, study design, and level of functional validation. Results: Across complications, EV-associated microRNAs appear to participate in shared pathogenic processes, including oxidative stress, inflammation, endothelial dysfunction, fibrosis, angiogenesis, neurodegeneration, and metabolic memory. In diabetic neuropathy, microRNAs such as miR-146a, miR-155, miR-21-5p, and miR-148a-3p have been linked to neuroinflammation, Schwann-cell dysfunction, axonal injury, and neuropathic pain. In diabetic kidney disease, miR-21, miR-29, miR-30, and miR-126 are implicated in podocyte injury, tubulointerstitial fibrosis, albuminuria, and microvascular dysfunction. In diabetic retinopathy, microRNAs including miR-146a, miR-155, miR-21, miR-126, and miR-200b contribute to neurovascular injury, inflammation, barrier disruption, and angiogenesis. In MASLD associated with diabetes, hepatocyte-derived EVs carrying microRNAs such as miR-1 and miR-126a-3p may link hepatic lipotoxicity to endothelial inflammatory and β-cell dysfunction. Conclusions: Although EV-associated microRNAs offer promising opportunities for biomarker discovery, risk stratification, and targeted therapies, clinical translation remains limited by heterogeneity in EV isolation, microRNA quantification, biological matrices, and outcome definitions. Distinguishing EV-associated miRNAs from total circulating extracellular miRNAs remains essential for biological interpretation. Standardized, longitudinal, and externally validated studies are required before these signals can be implemented as actionable tools in precision diabetes care.

6 June 2024 in Revista de la Sociedad Ecuatoriana de Nefrología, Diálisis y Trasplante
Verified
Journal Article
Open access
PDF file
DÁDiana Valderrama Ávila
Diana Valderrama Ávila
FJFrancisco Jesús Sevilla Jimenéz
Francisco Jesús Sevilla Jimenéz
WCWashington Xavier Osorio Chuquitarco
Washington Xavier Osorio Chuquitarco
MLMaribel Merino López
Maribel Merino López
EHEduardo Guerrero Hinzpeter
Eduardo Guerrero Hinzpeter
PGPablo Galindo
Pablo Galindo
Introduction: Critically ill patients who survive a severe episode of Acute Kidney Injury (AKI) recover sufficient renal function to allow withdrawal of Renal Replacement Therapy (RRT). However, the criteria for deciding its withdrawal need to be standardized in clinical practice. The study aimed to determine the factors associated with failure to disconnect in patients on continuous renal replacement therapy. Methods: This observational study was carried out in adult patients hospitalized in the intensive care service of the National Institute of Nutrition "Salvador Zubirán" in Mexico between October and December 2023 who required continuous renal replacement therapy. Retrospective data were collected, including demographic characteristics, comorbidities, type of renal replacement therapy, and clinical outcome. The SOFA score was used to assess disease severity. Results: A total of 18 patients were analyzed, 14 with unsuccessful disconnection and 4 with successful disconnection, with an average stay of 14±8 days in the ICU; 72% were men, 44% with a history of diabetes, and 72.2% with a history of high blood pressure. A total of 94.4% with vasopressor requirement and invasive mechanical ventilation. The primary RRT modality was CVVHDF (88.9%). The main indications for initiation were overload (38.9%) and anuria (44.4%). There were no differences between population characteristics or RRT modality. Differences in mortality were evident, probably explained by the greater severity of the patients, as evidenced by the more excellent SOFA upon admission (P=0.001). Conclusion: Patients who were unable to disconnect from the replacement therapy program had higher mortality. The factor that most contributed to this outcome was a higher SOFA score.